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a  b  s  t  r  a  c  t
Subunit  vaccines,  employing  puriﬁed  protein  antigens  rather  than  intact  pathogens,  require  the addi-
tion of adjuvants  for enhanced  immunogenicity  with  a correct  balance  between  strong  activation  of
the immune  system  and  low  toxicity.  Here  we  show  that the  endogenous  (i.e., autologous)  non-toxic
TLR4  agonist  extra  domain  A  type  III repeat  of ﬁbronectin  (FNIII  EDA)  can  synergize  with  the exoge-
nous  (i.e.,  bacterial),  toxic-at-high-dose,  TLR9  agonist  CpG  to  induce  efﬁcient  cellular  immune  responses
while  keeping  the  dose  of  CpG  low. The  efﬁcacy  of  the  combined  TLR  agonists,  even at  half-doses,  led  to
stronger  dendritic  cell  activation,  enhanced  cytotoxic  T  lymphocyte  activation  as  well  as stronger  humoraloll-like receptors
djuvant
daptive immunity
ancer vaccine
epatitis B virus
pG
response,  compared  to the individual  agonists  given  at full  doses.  Immune  cells  induced  after  vaccination
with  the  co-adjuvanted  formulation  could  mediate  tumor  regression  in an  E.G7-OVA  tumor  model,  and
eradicate circulating  hepatitis  B virus  (HBV)  in  a transgenic  HBV  model.  Together,  these  results  show  that
endogenous  TLR  agonists,  such  as variants  of  FNIII  EDA, can  synergize  with  exogenous  TLR  ligands,  such
as  CpG,  and  strongly  enhance  cellular  immune  responses,  while  improving  their  safety  proﬁle.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
NIII EDA
. Introduction
The beneﬁts of synthetic adjuvants toward improved vacci-
ation safety and efﬁcacy are indisputable, however the perfect
alance between activation of the immune system and side effects
emains somewhat elusive. A possible strategy to achieve this
esired balance would be the optimization of Toll-like receptor
TLR) agonist-based adjuvants [1]. The TLR9 agonist unmethylated
pG oligodeoxynucleotide induces the maturation of dendritic cells
DCs), leading to a potent B cell humoral response as well as the
ecretion of Th1-biasing cytokines [2]. Although safe at low doses
2,3], increasing the amount of CpG when the targeted disease
equires a stronger response has been associated with risks of
oxicity [4]. The endogenous (i.e.,  autologous, derived from the
ammal  itself) TLR4 agonist alternatively spliced type III repeat
xtra domain A of ﬁbronectin (FNIII EDA) [5] and its variant FNIII
∗ Corresponding author at: Institute for Molecular Engineering, University of
hicago, 5640 S. Ellis Avenue, Chicago, IL 60637, USA. Tel.: +(773)702-0585.
E-mail address: jhubbell@uchicago.edu (J.A. Hubbell).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.057
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access 
y-nc-nd/4.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
11-EDA have showed their ability to induce functional CD8+ T cell
responses without toxicity [6–8].
Although single TLR targeting strategies have shown promising
results, some combinations of TLR-agonists are known to syn-
ergize [9–13]. The strength, and most importantly the quality,
of the T cell response induced by speciﬁc combinations of TLR
agonists can be enhanced [13]. This signaling crosstalk can be pre-
dicted looking at the activation through MyD88 along with another
MyD88-independent signaling such as TRIF [10]. The MyD88 path-
way can be activated by most TLR ligands while the TRIF pathway
can be activated only by TLR3 and 4. We  thus hypothesized that a
combined administration of FNIII 11-EDA and CpG could synergize,
thus activating immune cells more efﬁciently than either alone,
allowing a reduction of the total dose of each adjuvant needed and
lowering inherent toxicity.
When tested in vitro, combination of FNIII 11-EDA and CpG
led to synergistic activation of dendritic cells (DCs), as measured
by the secretion of pro-inﬂammatory cytokines. Synergy was also
observed in vivo, where intradermal administration of the co-
adjuvanted vaccine led to a potent Th1 immune response through
activation of both CD4+ and CD8+ T cells, as well as an increase in
antibody production. When delivered as a therapeutic vaccine in an
E.G7-OVA tumor model, functional cytotoxic T lymphocytes (CTLs)
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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enerated by the co-adjuvanted vaccine induced tumor regres-
ion and led to an enhanced mouse survival. Finally, we  sought
o explore the ability of this TLR-agonist combination to break
mmune tolerance in a chronic hepatitis B transgenic mouse model
HBV-Tg) [14,15]. Immunization of HBV-Tg mice with hepatitis B
urface antigen (HBsAg) adjuvanted with a combination of CpG
nd FNIII 11-EDA induced a potent antiviral immune response,
s observed by the clearance of HBsAg from the circulation and
oncomitant development of anti-HBsAg antibodies.
Together, these results show that CpG and FNIII 11-EDA syn-
rgize toward an enhanced activation of the immune system in an
ntigen-speciﬁc manner, inducing tumor regression and increasing
BV seroconversion in therapeutic vaccine settings, while mini-
izing the dose of potentially toxic adjuvant.
. Methods
.1. Reagents and recombinant proteins
Low endotoxin grade OVA (<0.01 EU/g protein) was used
or immunization (Hyglos). CpG type-B 1826 oligonucleotide (5′-
CCATGACGTTCCTGACGTT-3′) was purchased from Microsynth AG
nd HBsAg from Prospec-Tany TechnoGene Ltd. FNIII 11-EDA was
roduced and puriﬁed as described by Julier et al. [6].
.2. Mice
C57BL/6J mice (aged 7–8 weeks) were purchased from Harlan
aboratories (France). Chi 1.3.32 (line 1.3.32, on a C57BL/6J back-
round, aged 7–10 weeks) mice replicating HBV at high levels in the
iver and kidneys, were kindly provided by Dr. Didier Trono (EPFL)
14]. Mice were kept under pathogen-free conditions at the animal
acility of EPFL. All experiments were performed in accordance with
wiss law and with approval from the Cantonal Veterinary Ofﬁce
f Canton de Vaud, Switzerland.
.3. In vitro stimulation of bone marrow-derived dendritic cells
BMDCs)
Murine BMDCs were generated as described elsewhere [16]. On
ay 8, 5 × 105 cells/well were plated on 96-well plates in DMEM
upplemented with 10% fetal bovine serum (FBS) and 1% peni-
illin/streptomycin (PS), and incubated for 6 h with 0, 0.5, 1 or
 M of CpG and/or recombinant FNIII 11-EDA. To block interac-
ions with any potentially contaminating LPS, FNIII 11-EDA was
re-incubated with 10 g/ml of polymixin B. Cytokines released in
he supernatant were measured by ELISA (eBioscience).
.4. Stimulation of antigen-speciﬁc response
C57BL/6J mice were immunized by intradermal injection in the
our footpads with a total dose of 50 g OVA adjuvanted with 40 g
f CpG (referred to as full-dose CpG) or 5 nmol (105 g) of FNIII 11-
DA (referred to as full-dose FNIII 11-EDA) or 20 g of CpG and
.5 nmol (52.5 g) of FNIII 11-EDA (referred to as half doses) com-
ined on day 0 and day 14. On day 19 mice were sacriﬁced, and
pleen, blood and/or liver were harvested for ex vivo restimulation
nd ﬂow cytometry staining.
.5. Ex vivo antigen-speciﬁc cell restimulation
Liver immune cells were isolated from hepatocytes by low speed
pins, and debris were removed using a 37.5% Percoll® (GE Health-
are) gradient. Blood, splenocytes, and liver cells were exposed
or 5 min  at r.t. to 0.155 M NH4Cl to lyse erythrocytes. For 6 h res-
imulation, immune cells were cultured ex vivo at 37 ◦C for 6 h in (2016) 2453–2459
the presence of 40 g/mL of HBsAg or 100 g/mL of OVA in full
media. After 3 h, Brefeldin-A (5 g/mL) was added and intracellular
cytokine production was  assessed by ﬂow cytometry. Restimula-
tion was also carried out over 3 days for measurement of secreted
cytokines by ELISA.
2.6. Tumor growth assays
106 E.G7-OVA tumor cells in 30 L PBS (Invitrogen) were
implanted s.c. in the back at the level of the junction between
the thoracic and lumbar vertebrae of C57BL/6J mice. Mice were
treated when their tumor reached 50 ± 5 mm3 and received a sec-
ond injection of the same treatment 6 days later. For this, mice
were immunized by injection in the four footpads with a total
dose of 50 g OVA adjuvanted with 40 g of CpG (referred to as
full-dose CpG) or 5 nmol (105 g) of FNIII 11-EDA (referred to as
full-dose FNIII 11-EDA) or 20 g of CpG and 2.5 nmol (52.5 g)
of FNIII 11-EDA or 20 g of CpG alone without FNIII 11-EDA.
Tumors were measured 5 times per week and volumes were cal-
culated as ellipsoids based on three orthogonal measures. Animal
were killed when the tumor reached 1000 mm3 or for humane
reasons such as tumor necrosis, excessive loss of weight or evi-
dent isolation from the other animals in accordance with Swiss
regulations.
2.7. Hepatitis B study
All experiments carried out with HBV-Tg mice were performed
in P2 and P3 biosafety levels. HBV-Tg mice were immunized by
intradermal injections in the four footpads with 10 g HBsAg adju-
vanted with 80 g of CpG (referred to as full-dose CpG) or 10 nmol
(210 g) of FNIII 11-EDA (referred as full-dose CpG) or 40 g of
CpG and 5 nmol (105 g) of FNIII 11-EDA (referred to as half-dose).
Here the dose of each adjuvant was  doubled compared to tumor
experiment, as preliminary experiments with this model showed
that relatively high doses were required. Mice were immunized
twice, on days 0 and 14. Mice were sacriﬁced on day 19 and liver
and spleen collected for ex vivo restimulation and ﬂow cytometric
analysis. Blood was  collected for ELISA analysis.
2.8. Flow cytometry and ELISA
Viable cells were detected by LIVE/DEAD (L/D) Fixable Aqua
stain (Invitrogen) and the following antibodies were used for sur-
face and intracellular staining: CD3 Paciﬁc Blue, CD4 FITC, CD8
APC-Cy7, IFN- APC, LAMP1 PE, TNF- PE (eBioscience), PE-labeled
H-2Kb/SIINFEKL pentamer (ProImmune). The following steps were
performed on ice. Cells were washed with PBS, stained for 15 min
with Aqua L/D stain, resuspended in PBS with 2% FBS for surface
staining for 15 min  and ﬁxed for 15 min  in PBS + 2% PFA. IFN- intra-
cellular staining was  performed in PBS + 2% FBS supplemented with
0.5% saponin. Flow cytometry was performed using a CyAn ADP
Analyzer (Beckman Coulter). Detection of HBsAg and IFN- were
performed using an HBsAg ELISA kit (AMS biotechnology) and a
Ready-Set-Go ELISA Kit (eBioscience), respectively, according to the
manufacturers protocol.
2.9. Data analysisFlow cytometry data was analyzed using FlowJo (TreeStar Inc.).
Graphing and statistical analyses – 1-way ANOVA with Bonferroni
post-test – were performed using GraphPad Prism (***P < 0.001;
**P < 0.01; *P < 0.05).
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Fig. 1. CpG and FNIII 11-EDA show synergistic activation of dendritic cells and stimulate strong IL-12p70, IL-6 and TNF- production. Secretion of IL-12p70 (A), IL-6 (B) and
TNF-  (C) by DCs in vitro after 6 h incubation with 0, 0.5, 1 or 2 M of CpG and/or recombinant FNIII 11-EDA. Data show ELISA readouts of measured and expected cytokine
concentrations as heat maps; color scales are indicated. Detailed values can be found in Fig. S1.
Fig. 2. FNIII 11-EDA and CpG are effective at inducing antigen-speciﬁc CD8+ T cell and Th1 responses in vivo. (A) Immunization schedule. C57BL/6J mice were immunized
by  intradermal injection in the four footpads with a total of 50 g of OVA adjuvanted with 40 g of CpG or 5 nmol (105 g) of FNIII 11-EDA or 20 g of CpG plus 2.5 nmol
(52.5  g) of FNIII 11-EDA on day 0 and 14. On day 19, mice were sacriﬁced, and the spleens were harvested. Data represent ﬂow cytometry measurements of (B) frequency
of  SIINFEKL-MHC-I-speciﬁc+ CD8+ T cells in the spleen, (C) frequency of IFN-+TNF-+ CD4+ splenocytes after 6 h ex vivo restimulation with OVA and (D, E) frequencies of
I NFEKL
m ,#P < 0
c
3
3
eFN-+ and IFN-+LAMP1+ CD8+ splenocytes after 6 h ex vivo restimulation with SII
easured by ELISA. Box plots represent means ±95% conﬁdence interval (n = 5). *
omparison to naïve group.
. Results.1. FNIII 11-EDA and CpG activate DCs in a synergistic manner
To determine whether FNIII 11-EDA and CpG were able to syn-
rgistically activate DCs, binomial combinations of both adjuvants. (F) IFN- production from splenocytes restimulated for 3 days ex vivo with OVA,
.05; **,##P < 0.01; ###P < 0.001; ns, not signiﬁcant; nd, not detectable; #, ##, ###,
were tested in vitro. Although FNIII 11-EDA or CpG alone induced
only mild activation of DCs at the doses tested (up to 2 M for
each CpG and FNIII 11-EDA), their combination led to synergis-
tic increases in the production of IL-12p70 (Fig. 1A, Fig. S1A), IL-6
(Fig. 1B, Fig. S1B), and TNF- (Fig. 1C, Fig. S1C). Indeed, combina-
tion of both agonists resulted in more than twice the expected
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Fig. 3. Multiple injections of OVA adjuvanted with both CpG and FNIII 11-EDA mediate regression of E.G7-OVA tumors. C57BL/6J mice were injected s.c. with 106 E.G7-OVA
cells  on the back. Mice were then treated with OVA or OVA adjuvanted either with combined half doses of CpG and FNIII 11-EDA or with full doses of each adjuvant alone or
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y  a dashed line. Mice were sacriﬁced when the tumor reached 1000 mm3 or for hum
ach  mouse in the different groups and (C) survival curve. Growth curves represent 
roup.
heoretical amount of cytokine secreted for most concentration
ombinations tested. Fig. S1 shows the actual measured concen-
rations of cytokines, from which the heat maps in Fig. 1 were
alculated.
.2. Co-immunization with FNIII 11-EDA and CpG induces potent
h1 response and increases cytotoxic activity of antigen-speciﬁc
D8+ T cells in vivo
We  next evaluated the ability of FNIII 11-EDA and CpG to
ynergize in vivo toward mounting a potent antigen-speciﬁc
esponse in mice using OVA as model antigen. Both vaccinat-
ng with full-dose CpG or combination of both adjuvants at
alf-doses induced signiﬁcantly higher levels of antigen-speciﬁc
SIINFEKL-MHCI-pentamers+) CD8+ T cells compared to full dose
f FNIII 11-EDA that had no observable effect (Fig. 2B). Fol-
owing ex vivo restimulation with OVA, combination of both
djuvants induced signiﬁcantly higher frequency of IFN-+TNF-
+ CD4+ T cells (Fig. 2C), compared to the other formulations.
ccordingly, the combination of adjuvants could induce a sig-
iﬁcant increase in IFN- producing CD8+ T cells (Fig. 2D) and
egranulating LAMP1+ CD8+ T cells (Fig. 2E) compared to sin-
le adjuvants. However, the total amount of IFN- produced by
plenocytes was  not signiﬁcantly enhanced compared to full dose
f CpG, but was  increased two folds compared to FNIII 11-EDA
Fig. 2F).received a second injection of the treatment 6 days later, represented on the ﬁgure
reasons. Data represent (A) average tumor volume, (B) individual growth curves for
 ± SEM; Kaplan–Meier survival-curves (n = 4–10). ***P < 0.001, relative to CpG + OVA
3.3. Immunization with OVA adjuvanted with CpG plus FNIII
11-EDA mediates regression of E.G7-OVA tumors through
functional cytotoxic T lymphocyte response
The level of functionality of CD8+ T cells generated after immu-
nization with the antigen combined to CpG and FNIII 11-EDA was
determined using the E.G7-OVA T cell lymphoma tumor model
expressing OVA as a surrogate antigen. Enhanced tumor regres-
sion was observed both in response to OVA adjuvanted with
full-dose CpG as well as half-doses of combined adjuvants as
shown on average (Fig. 3A) and individual (Fig. 3B) tumor growth
curves. Both groups temporarily showed strong tumor regression,
although regression was enhanced when both adjuvants were co-
administered. Tumor growth resumed faster when CpG was used
alone, whereas in mice treated with combined adjuvants the treat-
ment exerted control over tumor growth for a longer period of time
(Fig. 3C). OVA alone or supplemented with full-dose FNIII 11-EDA
had only a mild effect on tumor growth. In support of the syner-
gistic effect of FNIII 11-EDA and CpG, vaccination with OVA with
half-dose of CpG without FNIII 11-EDA also had only a mild effect
on tumor growth.
3.4. Immunization with HBsAg adjuvanted with CpG plus FNIII
11-EDA leads to strong Th1 cytokine secretion and limitation of
circulating viruses
To explore the ability of the combination of CpG plus FNIII
11-EDA to induce a T cell response capable of breaking immune
Z. Julier et al. / Vaccine 34 (2016) 2453–2459 2457
Fig. 4. Co-injection of HBsAg adjuvanted with the two TLR agonists CpG and FNIII 11-EDA leads to enhanced production of inﬂammatory cytokines by T cells and anti-HBsAg
seroconversion. (A) Immunization schedule. HBV-Tg mice were immunized by intradermal injection in the four footpads with 10 g HBsAg adjuvanted with 80 g of CpG or
10  nmol (210 g) of FNIII 11-EDA or 40 g of CpG and 5 nmol (105 g) of FNIII 11-EDA on day 0 and day 14. On day 19 mice were sacriﬁced, and spleens, livers and blood were
collected. (B) Anti-HBsAg IgGs levels in blood circulation and (C) concentration of HBsAg in the blood, as determined by ELISA. (D) Frequency of IFN-+TNF-+ CD4+ T cells
and  (E) IFN-+TNF-+ CD8+ T cells in the spleen after 6 h ex vivo restimulation with HBsAg, measured by ﬂow cytometry. (F) Magnitude of IFN- production from splenocytes
restimulated ex vivo for 3 days with HBsAg, evaluated by ELISA. Box plots represent means ±95% conﬁdence interval (n = 8). *P < 0.05; **P < 0.01; ns, not signiﬁcant; ##, ###,
comparison to naïve group.
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Folerance, the effect of the vaccine was assessed in HBV-Tg
ice. Therapeutic vaccination with combination of both adju-
ants and HBsAg led to a signiﬁcant increase in production of
nti-HBsAg IgGs (Fig. 4B) compared to all other groups. Vacci-
ation with full-dose FNIII 11-EDA, full-dose CpG and combined
alf-doses of each adjuvants signiﬁcantly affected and lowered
evels of circulating HBsAg in blood (Fig. 4C). However, the
ombination of both adjuvants improved the elimination of the
irally-produced protein compared to full-doses of each adju-
ant alone. Furthermore, half-dose of CpG without the addition
f FNIII 11-EDA was not sufﬁcient to achieve signiﬁcant reduction
f the amount of circulating HBsAg (Fig. S2E), similarly to HBsAg
nly.
Following ex vivo restimulation of splenocytes (Fig. 4D) or liver
ells (Fig. S2B) with HBsAg, a signiﬁcant increase in the frequency
f Th1 cytokine-secreting CD4+ T cells was observed in response to
o-vaccination with CpG and FNIII 11-EDA. While the frequency of
D8+ T cell secreting IFN- was higher when CpG was used as the
nly adjuvant (Fig. 4E), no difference in IFN--secreting CD8+ T cells
opulations in the liver was observed between the different treated
roups (Fig. S2C). However, the total amount of IFN- produced ex
ivo by restimulated splenocytes (Fig. 4F) and liver lymphocytes
Fig. S2D) was slightly increased by the combination of CpG and
NIII 11-EDA.4. Discussion
In this study, we  ﬁrst assessed the ability of CpG and FNIII 11-
EDA to activate DCs in a synergistic manner (Fig. 1, Fig. S1). Our
results indeed show that activation of DCs was  greatly enhanced in
response to co-stimulation with both adjuvants compared to stim-
ulation with each of them separately, as shown by the secretion of
IL-12p70 (Fig. 1A, Fig. S1A), IL-6 (Fig. 1B, Fig. S1B) and TNF- (Fig. 1C,
Fig. S1C). These results are interesting, as TLR synergies have been
reported to rely heavily on activation of the TRIF and MyD88 path-
ways [10]. Although FNIII EDA constructs induce the production of
TNF- [6], which expression is strictly MyD88-dependent [17], the
ability of FNIII 11-EDA to synergize with a TLR9 ligand indicate that
the TRIF pathway is also probably activated. This suggests that FNIII
11-EDA signals through both TRIF and MyD88 and would have the
potential to synergize with most TLR ligand [12].
To determine whether CpG and FNIII 11-EDA would synergize in
vivo and induce an enhanced antigen-speciﬁc CD8+ T cell response,
we used OVA as a model antigen in a vaccination study. Interest-
ingly, combination of half doses of CpG and FNIII 11-EDA was  able
to induce a comparable amount of antigen-speciﬁc CD8+ T cells
to that obtained with a complete dose of CpG (Fig. 2B), while also
leading to a higher quality response, as shown by the enhanced
effector phenotype observed (Fig. 2C–E). Moreover it is especially
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[16] Lutz MB,  Kukutsch N, Ogilvie ALJ, Rößner S, Koch F, Romani N, et al. An advanced458 Z. Julier et al. / Vacc
emarkable that after ex vivo restimulation, the Th1-cytokine
xpression proﬁle of CD4+ T cells (Fig. 2C) induced by the com-
ined half-doses was more than two-fold higher than the sum of
he average frequency obtained with full doses of each adjuvant
lone. A similar observation can be made on the average frequency
f IFN- expressing-CD8+ T cells (Fig. 2D, E) although these differ-
nces were much attenuated when observing secretion of IFN-
rom the total splenocytes population after 3 days of restimulation
Fig. 2F). These results show that the in vitro observations of synergy
etween CpG and FNIII 11-EDA can be translated in vivo to induce
 stronger or at least equivalent immune response while reducing
he dose of CpG.
Both CpG and FNIII 11-EDA are known to induce efﬁcient cellular
mmune responses capable of recognizing antigen-bearing targets
6,18]. Using the E.G7-OVA T cell lymphoma model we  assessed
he ability of both adjuvants to synergize in inducing an effec-
ive anti-tumor CD8+ T cell response (Fig. 3). The half-dose of CpG
ithout FNIII 11-EDA and full-dose FNIII 11-EDA used alone only
lightly slowed tumor growth. Full dose CpG alone induced tumor
egression, however growth resumed in all animals and none of
hem survived longer than 29 days. The majority of mice treated
ith both adjuvants together, however, lived longer than 33 days
ith one-third showing complete remission. It is also notewor-
hy that the tumors of more than half of the animals treated with
oth adjuvants temporarily regressed to undetectable levels before
esuming growth, whereas only one out of ten tumors treated
ith CpG alone regressed to that level. It is possible that tumor
scape in these animals was due to selective pressure leading to
he appearance of OVA-free tumors cells [19]. In addition, it would
e of interest to determine if increasing the number of injections
ould lead to complete remission of mice in the group treated
ith both adjuvants, as animals in these studies were treated only
wice.
To demonstrate whether the cellular response induced by this
ynergy was sufﬁciently strong to overcome immune tolerance, we
sed HBV-Tg mice, which are tolerized toward HBsAg [14,15]. In
his model, the combination of CpG and FNIII 11-EDA enhanced the
h1 proﬁle of the immune response both in the spleen and in the
iver (Fig. 4E, Fig. S2B) compared to CpG alone. It also induced sero-
onversion, as shown by the presence of anti-HBsAg IgGs (Fig. 4B)
n the blood. Together, these effects correlated with a signiﬁcant
eduction of circulating HBsAg proteins in the blood (Fig. 4C) in
ice receiving both adjuvants. The lack of complete elimination of
irculating HBsAg proteins can be explained by the fact that HBV
s replicated from an integrated transgene in this model, which
annot be eliminated [15].
Recent studies have demonstrated that the use of a second anti-
en, namely hepatitis B core antigen led to stronger responses
ue to B cells participation [20]. This strategy could enhance our
ormulations. Moreover our lab has recently demonstrated that
he conjugation of CpG to ultrasmall polymeric nanoparticles (NP)
nhanced Th1 and cytotoxic T cell responses while maintaining
 low dose of adjuvant. A synergy between NP-conjugated CpG
nd FNIII 11-EDA could further improve the safety proﬁle of new
accines [3,21,22]. Therapeutic vaccination in a disease such as
epatitis raises, however, questions of safety and especially of
onspeciﬁc T cell responses, which could potentially lead to liver
amage in this example [23]. In our studies in the model uti-
ized, we did not observe macroscopic effects of immune reactions
oward the liver, and transgenic mice did not show any obvious
igns of liver decompensation. This topic would, however, need
urther study to explore the extent to which the mounted immune
esponse is indeed HBV-speciﬁc.
Together these results show that CpG and FNIII 11-EDA have
he ability to synergize to break T cell tolerance and induce an
nhanced antigen speciﬁc response. It is important that these
[ (2016) 2453–2459
improved effects were obtained while lowering the total dose of the
foreign agent CpG, opening the door to the development of potent
immunotherapies with fewer side effects and improved safety.
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